Clinical Trials
136 trialsNCT04634552 2026-06-05
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05160584 2026-06-05
MoMMent
Janssen Pharmaceutica N.V., Belgium
Recruiting
NCT05201781 2026-06-05
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
NCT05438043 2026-06-05
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05552222 2026-06-05
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05650632 2026-06-05
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT05652335 2026-06-05
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06057402 2026-06-05
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT06152575 2026-06-05
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06158841 2026-06-05
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-06-05
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06285318 2026-06-05
REALiTEC/TAL
Janssen-Cilag Ltd.
Recruiting
NCT06500884 2026-06-05
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07030517 2026-06-05
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
Phase 4 Recruiting
NCT07149857 2026-06-05
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07258511 2026-06-05
TRIlogy-4
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07266441 2026-06-05
TRIlogy-3
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07518186 2026-06-05
TRIlogy-5
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06615479 2026-06-04
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07255898 2026-06-04
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07490613 2026-06-04
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05519085 2026-06-03
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT05583617 2026-06-03
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05927571 2026-06-03
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT06106945 2026-06-02
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca
Phase 1/2 Recruiting
NCT06953960 2026-06-02
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1/2 Recruiting
NCT07095452 2026-06-02
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT07227311 2026-06-02
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Recruiting
NCT06297226 2026-05-28
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT06988488 2026-05-28
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1/2 Recruiting
NCT07073547 2026-05-27
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
AstraZeneca
Phase 1 Recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT05714839 2026-05-22
DREAMM-20
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06215118 2026-05-22
MagnetisMM-30
Pfizer
Phase 1 Recruiting
NCT07138209 2026-05-22
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07477587 2026-05-22
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech
Phase 1 Recruiting
NCT06433947 2026-05-19
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Opna Bio LLC
Phase 1 Recruiting
NCT07409246 2026-05-19
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1 Recruiting
NCT06980480 2026-05-18
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Takeda
Phase 3 Recruiting
NCT07116616 2026-05-18
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT05623020 2026-05-14
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT05828511 2026-05-13
LINKER-MM4
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06896916 2026-05-12
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT07579234 2026-05-12
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 3 Recruiting
NCT07582432 2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3 Recruiting
NCT04973605 2026-05-11
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT06934044 2026-05-11
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1 Recruiting
NCT06768489 2026-05-08
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06413498 2026-05-07
iMMagine-3
Gilead Sciences
Phase 3 Recruiting
NCT05850234 2026-05-06
DURGA-1
AstraZeneca
Phase 1/2 Recruiting